Exchange: NYSE·Updated 09:34 AM EDT
News
all
press releases
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
Zacks
More News
Why Is Align Technology (ALGN) Down 8.4% Since Last Earnings Report?
Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Zacks
Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up
VEEV's Q2 fiscal 2027 earnings and revenues top estimates, while strong Vault CRM momentum and a raised full-year outlook drive shares higher.
Zacks
McKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks
West to Participate in Upcoming Investor Conferences
West to Participate in Upcoming Investor Conferences West to Participate in Upcoming Investor Conferences PR Newswire EXTON, Pa., Aug. 26, 2026 EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug...
PR Newswire
DVA & Humana Expand Value-Based Care for Kidney Disease Patients
DaVita expands its Humana partnership to earlier-stage kidney disease, bringing value-based care to over 10,000 Medicare Advantage members.
Zacks
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MCK's specialty distribution, oncology and technology businesses are fueling growth, while drug-pricing pressure and policy shifts pose risks.
Zacks
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Zacks
Reasons to Retain Doximity Stock in Your Portfolio for Now
DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
Zacks

Advertisement|Remove ads.